Barrett’s Esophagus Clinic Security Risk Assessment Checklist

Use this clinical checklist to organize Barrett’s esophagus (BE) risk assessment, screening decisions, diagnostic findings, and follow-up. It supports—not replaces—individual clinical judgment and shared decision-making.

Which patient risk factors should the assessment checklist capture?

Record the patient’s reflux history and risk factors associated with BE and esophageal adenocarcinoma (EAC). These factors help clinicians decide whether screening may be appropriate; they do not establish a diagnosis.

• Chronic gastroesophageal reflux symptoms: Document how long symptoms have occurred and how often they arise.
• Age and sex: Note age over 50 and male sex, which are among recognized risk factors.
• Family history: Ask about BE or EAC in a first-degree relative, such as a parent, sibling, or child.
• Tobacco use: Record current and past smoking history.
• Obesity: Assess whether the patient has obesity, including central or abdominal obesity.
• Race and ethnicity: Record information relevant to established risk criteria, while recognizing that risk factors should inform—not determine—care.

The 2022 American College of Gastroenterology (ACG) guideline identifies chronic reflux plus three or more additional risk factors as a basis to consider a single screening endoscopy. The American Gastroenterological Association (AGA) clinical practice update also describes established risk factors, including reflux, age over 50, male sex, smoking, obesity, and family history.

How can clinicians assess reflux history and additional risk factors?

Ask about the frequency and duration of heartburn or acid regurgitation, prior reflux evaluations, and treatment history. Record smoking exposure, weight-related risk, and whether a first-degree relative had BE or EAC. A consistent history makes it easier to apply screening criteria and revisit the decision over time.

Distinguish screening—testing a person without a known diagnosis—from endoscopy prompted by concerning symptoms or another clinical indication. A risk checklist alone cannot diagnose BE or rule out other causes of symptoms. The ACG’s patient information on Barrett’s esophagus summarizes recognized risk factors and the role of screening discussions.

When should screening endoscopy be considered?

For a patient with chronic reflux symptoms and at least three additional established risk factors, clinicians may consider a one-time screening endoscopy. Discuss the patient’s overall health, life expectancy, preferences, and whether finding BE would lead to surveillance or treatment. Screening is a decision to consider—not an automatic requirement for everyone with reflux.

Use the endoscopic segment length threshold carefully when interpreting results: a columnar-appearing segment under 1 cm should not ordinarily be labeled or surveilled as BE solely because intestinal metaplasia is found there. The ACG guideline sets out screening and diagnostic criteria; the 2025 AGA surveillance guideline advises against surveillance for columnar-lined esophagus under 1 cm without neoplasia.

What findings and biopsies confirm Barrett’s esophagus?

In U.S. guidance, diagnosis requires both an endoscopic finding and tissue confirmation: at least 1 cm of visible columnar mucosa extending into the tubular esophagus above the gastroesophageal junction, plus intestinal metaplasia in the tubular esophagus on biopsy. Intestinal metaplasia in the tubular esophagus is a histologic finding; it should be interpreted alongside the endoscopic landmarks and measured segment.

Document the gastroesophageal junction and the circumferential and maximal extent of the columnar segment, commonly using the Prague classification. During a high-quality examination, use high-definition white-light endoscopy to inspect the esophagus carefully, describe visible abnormalities, and sample any suspicious lesions. The ACG diagnostic guideline advises against routine biopsy of a normal Z line or an irregular Z line with less than 1 cm of variation when there is no visible lesion.

Use a structured biopsy approach. The Seattle biopsy protocol includes targeted sampling of visible abnormalities and systematic four-quadrant biopsies—typically every 2 cm when there is no dysplasia, and every 1 cm when dysplasia has previously been identified. The 2025 AGA guideline recommends combining high-definition white-light endoscopy with chromoendoscopy during surveillance; chromoendoscopy-directed biopsies supplement, rather than replace, structured sampling.

How should surveillance for nondysplastic Barrett’s esophagus be planned?

For confirmed nondysplastic BE, base the surveillance plan on segment length, examination quality, pathology, the patient’s health, and preferences. The 2025 AGA guideline suggests surveillance and notes that many experts advise a high-quality endoscopy about every 3 years, with an interval as long as 5 years potentially appropriate for lower-risk patients, such as those with short-segment BE under 3 cm. The guideline also advises considering discontinuation as age and comorbidities change the balance of potential benefit and risk.

At follow-up, carefully inspect the segment with high-definition white-light endoscopy and chromoendoscopy, document its length, target visible abnormalities, and complete systematic biopsies. If dysplasia is reported, expert pathology review and a separate management plan are important; dysplastic BE does not follow the nondysplastic schedule. See the AGA’s 2025 clinical practice guideline for current surveillance recommendations and implementation considerations.

What are the checklist’s limitations in clinical decision-making?

This checklist helps structure information but cannot calculate an individual’s risk, confirm BE, or determine whether endoscopy is appropriate in every case. Screening recommendations depend on clinical context, and evidence for some decisions—including optimal surveillance intervals—is limited. Endoscopy and pathology quality also affect whether findings are detected and classified accurately.

Use the checklist as a prompt for clinician-patient discussion, not as a substitute for examination, pathology review, or current professional guidance. In summary, capture relevant reflux and additional risk factors, apply the 1 cm diagnostic threshold, confirm tissue findings, and individualize surveillance according to segment length, pathology, health, and patient preferences.

FAQs

Which risk factors should be included in a Barrett’s esophagus assessment?

Include chronic reflux symptoms, age over 50, male sex, smoking history, obesity, race and ethnicity relevant to established risk criteria, and a first-degree family history of BE or EAC. These factors guide screening discussions but do not diagnose BE.

When may screening endoscopy be considered?

Clinicians may consider a one-time screening endoscopy for a person with chronic reflux symptoms and at least three additional established risk factors. The decision should also account for overall health, life expectancy, preferences, and whether a diagnosis would change care.

What findings are required to confirm Barrett’s esophagus?

U.S. guidance requires at least 1 cm of visible columnar mucosa in the tubular esophagus and biopsy confirmation of intestinal metaplasia in that esophageal tissue. A finding confined to a columnar-lined segment under 1 cm does not ordinarily meet the diagnostic threshold.

How is nondysplastic Barrett’s esophagus monitored?

Surveillance uses careful high-definition white-light examination with chromoendoscopy and structured biopsies, including the Seattle protocol. The 2025 AGA guideline describes about 3 years as a common interval, with up to 5 years potentially suitable for lower-risk short-segment BE; clinicians should individualize timing and consider age and comorbidities.